|Table of Contents|

Expression and clinical significance of Tim-3 on CD8+T cell from peripheral blood of melanoma patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 05
Page:
793-797
Research Field:
Publishing date:

Info

Title:
Expression and clinical significance of Tim-3 on CD8+T cell from peripheral blood of melanoma patients
Author(s):
Gao Xiaoyan; Yan Wanjun; Ma Xingcong; Ma Yi'nan; Ren Hongtao; Xue Xinghuan; Zhang Shuqun
Department of Oncology，The Second Affiliated Hospital of Xi'an Jiaotong University，Shaanxi Xi'an 710004，China.
Keywords:
Tim-3; CD8+T cells; malignant melanoma; flow cytometry
PACS:
R739.5
DOI:
10.3969/j.issn.1672-4992.2017.05.032
Abstract:
Objective：To explore the role of T cell immunoglobulin and mucin domain molecules-3（Tim-3) in malignant melanoma progression via detecting Tim-3 expression on CD8+ T Cells from peripheral blood of malignant melanoma patients.Methods：Detect Tim-3 expression on CD8+ T cells from peripheral blood of 42 malignant melanoma patients and 38 healthy volunteers using flow cytometry，and analyze its relationship with clinical pathological features of the malignant melanoma patients.Results：The expression of Tim-3 CD8+T cell existed in both malignant melanoma patients and healthy volunteers，however，the proportion of Tim-3 CD8+T cell in malignant melanoma group(15.89±6.49)% was significantly higher than the control group（3.27±2.16)%,P<0.01.Higher expression of Tim-3 CD8+T cells in peripheral blood mononuclear cell was related to ulceration，lymph node metastasis，TNM stage，and distant metastasis in malignant melanoma patients（P<0.01)，but not related to gender and age（P>0.05 ).Conclusion：Malignant melanoma patient's peripheral blood CD8+T cell expressed higher levels of Tim-3 compared to healthy donors，moreover，the expression level had positive correlation with TNM stage.Tim-3 may be a valuable molecular marker and an important therapeutic target.

References:

［1］Villanueva J，Herlyn M.Melanoma and the tumor microenvironment［J］.Curr Oncol Rep，2008，10（5)：439-446.
［2］Nikolaou VA，Stratigos AJ，Flaherty KT，et al.Melanoma：new insights and new therapies［J］.J Invest Dermatol，2012，132（3 Pt 2)：854-863.
［3］Chapman PB，Hauschild A，Robert C，et al.Improved survival with vemurafenib in melanoma with BRAF V600E mutation［J］.N Engl J Med，2011，364（26)：2507-2516.
［4］Hodi FS，O'Day SJ，McDermott DF，et al.Improved survival with ipilimumab in patients with metastatic melanoma［J］.N Engl J Med，2010，363（8)：711-723.
［5］Vesely MD，Kershaw MH，Schreiber RD，et al.Natural innate and adaptive immunity to cancer［J］.Annu Rev Immunol，2011，29：235-271.
［6］Qureshi OS，Zheng Y，Nakamura K，et al.Trans-endocytosis of CD80 and CD86：a molecular basis for the cell-extrinsic function of CTLA-4［J］.Science，2011，332（6029)：600-603.
［7］Wherry EJ.T cell exhaustion［J］.Nat Immunol，2011，12（6)：492-499.
［8］Fourcade J，Sun Z，Benallaoua M，et al.Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+T cell dysfunction in melanoma patients［J］.J Exp Med，2010，207（10)：2175-2186.
［9］Monney L，Sabatos CA，Gaglia JL，et al.Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease［J］.Nature，2002，415（6871)：536-541.
［10］Ngiow SF，von Scheidt B，Akiba H，et al.Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors［J］.Cancer Res，2011，71（10)：3540-3551.
［11］Yang ZZ，Grote DM，Ziesmer SC，et al.IL-12 upregulates Tim-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma［J］.J Clin Invest，2012，122（4)：1271-1282.
［12］Sakuishi K，Apetoh L，Sullivan JM，et al.Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity［J］.J Exp Med，2010，207（10)：2187-2194.
［13］Zhu C，Anderson AC，Schubart A，et al.The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity［J］.Nat Immunol，2005，6（12)：1245-1252.
［14］Sanchez-Fueyo A，Tian J，Picarella D，et al.Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance［J］.Nat Immunol，2003，4（11)：1093-1101.
［15］Huang X，Bai X，Cao Y，et al.Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion［J］.J Exp Med，2010，207（3)：505-520.
［16］Marquez-Rodas I，Cerezuela P，Soria A，et al.Immune checkpoint inhibitors：therapeutic advances in melanoma［J］.Ann Transl Med，2015，3（18)：267.
［17］Yan J，Zhang Y，Zhang JP，et al.Tim-3 expression defines regulatory T cells in human tumors［J］.PLoS One，2013，8（3)：e58006.
［18］Bai J，Li X，Tong D，et al.T-cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and prognosis of non-small-cell lung cancer［J］.Tumour Biol，2013，34（2)：805-809.
［19］Song H，Ma S，Cha Z，et al.T-cell immunoglobulin- and mucin-domain-containing molecule 3 genetic variants and HIV+ non-Hodgkin lymphomas［J］.Inflammation，2013，36（4)：793-799.
［20］Jinhua X，Ji W，Shouliang C，et al.Expression of immune checkpoints in T cells of esophageal cancer patients［J］.Oncotarget，2016，7（39)：63669-63678.
［21］Severson JJ，Serracino HS，Mateescu V，et al.PD-1+Tim-3+ CD8+ T lymphocytes display varied degrees of functional exhaustion in patients with regionally metastatic differentiated thyroid cancer［J］.Cancer Immunol Res，2015，3（6)：620-630.
［22］Baghdadi M，Nagao H，Yoshiyama H，et al.Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas［J］.Cancer Immunol Immunother，2013，62（4)：629-637.

Memo

Memo:
国家自然科学基金面上项目（编号：81274136）；西安交通大学交叉项目基金(编号：Xjj2012141)
Last Update: 2017-01-26